GU Cancers 2023 | Unanswered questions for the use of PSMA PET in the staging of prostate cancer

David M. Nanus, MD, Weill Cornell Medicine and New York Presbyterian Hospital, New York City, NY, talks on the current uses of PSMA PET scans in prostate cancer, such as in the staging of newly diagnosed, high-risk patients or those with non-metastatic castrate-resistant prostate cancer (CRPC). Dr Nanus discusses the utility of PSMA PET compared to conventional imaging techniques, and explores the potential of using PSMA PET to detect oligometastatic disease or assess response to treatment. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.